TNFRSF1A and metabolic dysfunction-associated steatohepatitis: Our data demonstrate that TNFR1 inhibition through Atrosimab administration efficiently blocked TNFR1-mediated inflammatory responses in a model of acute TNF-mediated inflammation and in experimental arthritis, NASH and EAE.